CompletedPhase 2

Fatigue and Interleukin-1 (IL-1) Blockade in Primary Sjøgrens Syndrome

Norway28 participantsStarted 2008-01

Plain-language summary

Fatigue is a prevalent phenomenon in Primary Sjøgrens syndrome (PSS). Observations indicate that the cytokine IL-1 is of importance for this phenomenon. In this study the investigators block IL-1 by giving Anakinra (an IL-1 receptor antagonist) to patients with PSS.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Primary Sjøgrens Syndrome according to the European-American criteria * Age 18-80 years * Written informed consent Exclusion Criteria: * Hyper- og hypothyreosis * Malignant disease * Parkinsons disease * Multiple sclerosis * Conditions or diseases where Anakinra is contraindicated * Mental depression (BDI \>13) * Neutropenia (\<1.5\*10.9) * Frequent infections * Pregnancy, lactating women.

What they're measuring

Fatigue as measured by Fatigue Severity Scale and a visual analogue fatigue scale

Timeframe: 4 weeks

Trial details

NCT IDNCT00683345

SponsorHelse Stavanger HF

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2010-04

View on ClinicalTrials.gov More Fatigue trials